Preclinical evidence suggests β-glucan might synergize with PD-1/PD-L1 inhibitors by transforming “cold” tumors to “hot”—combining β-glucan with anti-PD-L1 therapy significantly extended survival in murine pancreatic cancer [49]. This evidence concerns the gene CD274 and familial pancreatic carcinoma.